DEFINING LOW-RISK HIGH HYPERDIPLOIDY IN PAEDIATRIC PATIENTS WITH ALL
In childhood acute lymphoblastic leukaemia (ALL), high hyperdiploidy accounts for a large proportion of all relapses. However, thus far there was no consensus regarding the optimal risk factors in patients with high hyperdiploid ALL. A retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials now identified and validated a clinically useful profile, based on four constituent trisomies, to identify low-risk patients with high hyperdiploid ALL… Read more
NEW INSIGHTS IN CLINICAL OUTCOMES OF PATIENTS WITH ALL AND DOWN SYNDROME
A recent multinational cohort study addressed minimal residual disease (MRD) and long-term clinical outcomes in Down syndrome and non-Down syndrome patients with acute lymphocytic leukaemia (ALL), matched according to clinical risk factors and genetics. Results demonstrated that MRD levels at the end of induction are similar between individuals with and without Down syndrome. Furthermore, findings show that Down syndrome itself provides an additional risk of relapse in patients with IKZF1 deletion… Read more
CD19-TARGETED CAR-T THERAPY FOR CNS RELAPSED OR REFRACTORY ALL
To date, durable remissions of relapsed or refractory B-cell acute lymphocytic leukaemia (R/R ALL) have been observed following treatment with CD19-directed chimeric antigen receptor (CAR) T cells. However, since most trials have excluded patients with active central nervous system (CNS) disease, little is known on this patient population. A post-hoc analysis of pooled data from five clinical trials now assessed the safety and activity of CAR-T cell therapy in patients with a history of CNS R/R ALL… Read more
CAR-T THERAPY BRIDGED TO HAPLO-HSCT IMPROVES SURVIVAL OF CHILDREN WITH R/R B-ALL
In order to improve survival outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia (R/R ALL), there is a high need for novel and durable treatment regimens. A recent study of a relatively large patient series (N= 52) now demonstrated that CAR-T therapy bridged to haploidentical haematopoietic stem cell transplantation (haplo-HSCT) could improve the survival of children and young adult R/R B-ALL patients, without increased transplant-related mortality rates… Read more
AUTOLOGOUS CAT19-41BB-Z CAR-T CELLS AS A STAND-ALONE TREATMENT FOR R/R ADULT B-ALL
Prognosis for adult B-cell acute lymphoblastic leukaemia (B-ALL) is poor, and there are currently no licensed CD19 chimeric antigen receptor (CAR) therapeutics. In the phase I ALLCAR19 study, Autologous CAT19-41BB-Z CAR-T cells (AUTO1) now demonstrates a tolerable safety profile, high remission rates, and good persistence in adult patients with relapsed/refractory B-ALL and support AUTO1 as a stand-alone treatment in this population… Read more
Top
